Statement on the recommended use of pentavalent and hexavalent vaccines. An Advisory Committee Statement (ACS).
D002170:Canada; D004165:Diphtheria / Q000517:prevention & control; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000627:therapeutic use*; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000627:therapeutic use; D006192:Haemophilus Infections / Q000517:prevention & control; D018073:Haemophilus Vaccines / Q000627:therapeutic use*; D006509:Hepatitis B / Q000517:prevention & control; D017325:Hepatitis B Vaccines / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D011051:Poliomyelitis / Q000517:prevention & control; D011054:Poliovirus Vaccine, Inactivated; D023321:Poliovirus Vaccines / Q000627:therapeutic use*; D013742:Tetanus / Q000517:prevention & control; D017778:Vaccines, Combined / Q000627:therapeutic use*; D014917:Whooping Cough / Q000517:prevention & control
D015721:Diphtheria-Tetanus-Pertussis Vaccine; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D018073:Haemophilus Vaccines; D017325:Hepatitis B Vaccines; D011054:Poliovirus Vaccine, Inactivated; D023321:Poliovirus Vaccines; D017778:Vaccines, Combined; C512971:pentacel